Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Trading Update

13 Nov 2019 07:00

RNS Number : 1857T
Ideagen PLC
13 November 2019
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

13 November 2019

Ideagen PLC

("Ideagen" "the Company" or "the Group")

Trading Update

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, today provides an update on trading for the six months ended 31 October 2019.

The Board is pleased to report that trading has remained strong in the first half of the financial year and that revenue and EBITDA are both expected to be significantly ahead of the same period last year and in line with management's expectations. This has been achieved through both organic revenue growth and the acquisitions of Redland Business Solutions Ltd (acquired in June 2019) and Optima Diagnostics Ltd (acquired in Oct 2019). The Company has a clear strategy to grow revenues organically and maintain high EBITDA margins whilst transitioning from a perpetual licence to a SaaS based subscription model. The successful execution of this strategy will provide an even more robust business model and a higher quality of earnings over the medium term without impacting on the short-term profitability of the business.

The Board considers that the key growth metric for the Group is based on Annual Recurring Revenue ("ARR"). ARR is the value of the Group's contracted recurring revenue book at any point in time, which will be recognised over the next 12 month period.

The Group's ARR has grown by approximately 20 per cent. from £36.4 million on 30 April 2019 to £43.9 million on 31 October 2019. This comprises of acquisition-led growth of £3.8 million combined with organic growth of £3.7 million within the period, representing approximately a 20 per cent. organic growth rate on an annualised basis. Group performance is based on strong customer demand and sales execution in the period and indicates that the transition to a recurring model is progressing successfully and is ahead of schedule.

Total organic revenue growth in the period was 7 per cent. which, in the context of an accelerated SaaS transition, represents a strong performance. Recognised Recurring revenue is expected to be approximately 74 per cent. of total revenue and is expected to rise to over 80 per cent. in the next full financial year.

The Company continues to compete and win new business within the UK and international markets reflecting the Company's global expansion. During the period, the Company won over 240 new customer logos including Emirates Airline, Emirates Catering, Alexander Hall, Mallinckrodt Pharmaceuticals, Freightliner, Vietjet Air, Mylan Pharmaceuticals and Royal London.

At the period end the group had net debt of £18.2 million (30 April 2019: net debt of £1.3 million) after spending £19.8 million on acquisitions. Operating cash generation in the period remained robust and in line with the Board's expectations. 

Ben Dorks, Chief Executive Officer of Ideagen, commented:

"I am pleased to report an excellent start to Ideagen's financial year. Our core markets are strong and underpin the demand we have seen this half. We continue to execute our strategy, delivering growth and investing in the business whilst tightly managing the cost base. The Company has continued to make acquisitions which have further enhanced our global reach, customer base and product capability.

Cash generation has been good which coupled with further growth in new SaaS recurring revenues and an increase in repeat business from our growing customer base provides a strong platform for the second half.

The market opportunity remains large and long term and given the Group's position as a leader in the Governance, Risk and Compliance market, the Board is optimistic about the Group's continued growth prospects."

 Enquiries:

Ideagen plc

01629 699100

David Hornsby, Executive Chairman

Ben Dorks, Chief Executive Officer

Graeme Spenceley, Chief Financial Officer

 finnCap Limited

020 7220 0500

Henrik Persson/James Thompson (Nomad)

Alice Lane (ECM)

 

Canaccord Genuity Limited

 020 7523 8000

Simon Bridges

Richard Andrews

About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides IRM software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 4,700 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTVLLFFKFFZFBE
Date   Source Headline
24th Sep 201810:42 amRNSHolding(s) in Company
17th Sep 20184:42 pmRNSExercise of Options and Total Voting Rights
17th Sep 20184:33 pmRNSHolding(s) in Company
13th Sep 20185:00 pmRNSClosing of conditional Placing to raise £20m
13th Sep 201811:30 amRNSProposed Placing to raise £20 million
5th Sep 20187:00 amRNSAcquisition of InspectionXpert Inc
3rd Sep 20182:36 pmRNSExercise of Options and Total Voting Rights
15th Aug 201812:23 pmRNSHolding(s) in Company
13th Aug 20183:18 pmRNSHolding(s) in Company
13th Aug 20183:05 pmRNSIssue of Shares under Share Incentive Plan and TVR
7th Aug 20181:08 pmRNSHolding(s) in Company
23rd Jul 20183:27 pmRNSIssue of Equity
17th Jul 20187:00 amRNSUnaudited Preliminary Results
18th Jun 20183:38 pmRNSExercise of Options and Total Voting Rights
11th Jun 20185:00 pmRNSIssue of Equity and Total Voting Rights
22nd May 20183:59 pmRNSIssue of Shares under Share Incentive Plan and TVR
15th May 20183:10 pmRNSExercise of Options and Total Voting Rights
9th May 20187:00 amRNSExercise of Options and Total Voting Rights
8th May 20187:00 amRNSPre-Close Trading Update and Board Changes
18th Apr 201810:12 amRNSIssue of Equity
12th Apr 201810:35 amRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSDirector/PDMR Shareholding
6th Apr 20187:00 amRNSAcquisition of Medforce Technologies Inc
26th Mar 201812:38 pmRNSHolding(s) in Company
16th Mar 20187:00 amRNSIssue of Shares under Share Incentive Plan and TVR
6th Mar 20183:58 pmRNSExercise of Options and Total Voting Rights
14th Feb 20187:00 amRNSIssue of Equity
23rd Jan 20187:00 amRNSInterim Results
11th Jan 20187:00 amRNSIssue of Equity
13th Dec 201710:18 amRNSDirector Dealing
11th Dec 20172:26 pmRNSIssue of Equity
4th Dec 201712:37 pmRNSExercise of Options and Total Voting Rights
23rd Nov 20177:00 amRNSContract Win
10th Nov 20173:07 pmRNSIssue of Shares under Share Incentive Plan and TVR
7th Nov 20171:26 pmRNSExercise of Options and Total Voting Rights
7th Nov 20177:00 amRNSTrading Update
1st Nov 20175:18 pmRNSPDMR / PCA Dealing
30th Oct 20171:33 pmRNSResult of AGM
25th Oct 20177:00 amRNSExercise of Options and Total Voting Rights
23rd Oct 201710:55 amRNSExercise of Options and Total Voting Rights
16th Oct 20173:30 pmRNSExercise of Options and Total Voting Rights
9th Oct 20174:09 pmRNSIssue of shares under the Share Incentive Plan
6th Oct 20173:13 pmRNSNotice of AGM
27th Sep 20174:28 pmRNSExercise of Options and Total Voting Rights
20th Sep 201710:08 amRNSHolding(s) in Company
4th Sep 20177:00 amRNSBoard Appointment
1st Sep 20173:06 pmRNSIssue of shares under a Share Incentive Plan
11th Aug 20173:00 pmRNSHolding(s) in Company
11th Aug 20178:00 amRNSHolding(s) in Company
10th Aug 20171:36 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.